WO2018216705A1 - Agent prophylactique et/ou thérapeutique contre des maladies neurodégénératives - Google Patents

Agent prophylactique et/ou thérapeutique contre des maladies neurodégénératives Download PDF

Info

Publication number
WO2018216705A1
WO2018216705A1 PCT/JP2018/019726 JP2018019726W WO2018216705A1 WO 2018216705 A1 WO2018216705 A1 WO 2018216705A1 JP 2018019726 W JP2018019726 W JP 2018019726W WO 2018216705 A1 WO2018216705 A1 WO 2018216705A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
amino
pyridinyl
phenyl
pyrimidinyl
Prior art date
Application number
PCT/JP2018/019726
Other languages
English (en)
Japanese (ja)
Inventor
治久 井上
恵子 今村
Original Assignee
国立大学法人京都大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 国立大学法人京都大学 filed Critical 国立大学法人京都大学
Priority to JP2019520270A priority Critical patent/JPWO2018216705A1/ja
Publication of WO2018216705A1 publication Critical patent/WO2018216705A1/fr
Priority to JP2022113647A priority patent/JP7398831B2/ja

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

La présente invention concerne un agent prophylactique et/ou thérapeutique contre une maladie neurodégénérative appartenant au groupe constitué par la maladie d'Alzheimer, les dégénérescences lobaires fronto-temporales et les α-synucléinopathies, ledit agent contenant au moins un inhibiteur de la voie Src/c-Ab1.
PCT/JP2018/019726 2017-05-23 2018-05-22 Agent prophylactique et/ou thérapeutique contre des maladies neurodégénératives WO2018216705A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2019520270A JPWO2018216705A1 (ja) 2017-05-23 2018-05-22 神経変性疾患の予防及び／又は治療剤
JP2022113647A JP7398831B2 (ja) 2017-05-23 2022-07-15 神経変性疾患の予防及び／又は治療剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017-102176 2017-05-23
JP2017102176 2017-05-23

Publications (1)

Publication Number Publication Date
WO2018216705A1 true WO2018216705A1 (fr) 2018-11-29

Family

ID=64395728

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/019726 WO2018216705A1 (fr) 2017-05-23 2018-05-22 Agent prophylactique et/ou thérapeutique contre des maladies neurodégénératives

Country Status (2)

Country Link
JP (2) JPWO2018216705A1 (fr)
WO (1) WO2018216705A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020241772A1 (fr) * 2019-05-31 2020-12-03 国立大学法人京都大学 Dispositif de traitement d'informations, dispositif de criblage, procédé de traitement d'informations, procédé de criblage, et programme
WO2020241836A1 (fr) * 2019-05-31 2020-12-03 国立大学法人京都大学 Dispositif de traitement d'informations, dispositif de criblage, procédé de traitement d'informations, procédé de criblage, et programme
WO2022124247A1 (fr) 2020-12-09 2022-06-16 国立大学法人 東京医科歯科大学 Agent de prévention ou de traitement de la dégénérescence lobaire fronto-temporale
JP2022137234A (ja) * 2017-05-23 2022-09-21 国立大学法人京都大学 神経変性疾患の予防及び／又は治療剤

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008504022A (ja) * 2004-06-21 2008-02-14 プロティオーム・サイエンシィズ・ピーエルシー スクリーニング方法
JP2008511304A (ja) * 2004-09-02 2008-04-17 ニューロ セラピューティクス エービー ドーパミンニューロンの増強産生に関する方法と材料
JP2010505816A (ja) * 2006-10-03 2010-02-25 ヌリム・ファーマスーティカルズ・（１９９１）・リミテッド 治療薬剤としての置換アリール−インドール化合物とそのキヌレニン／キヌラミン様代謝産物
WO2013166295A1 (fr) * 2012-05-02 2013-11-07 Georgetown University Traitement d'une maladie neurale avec des inhibiteurs de tyrosine kinase
JP2014502601A (ja) * 2010-12-17 2014-02-03 エフ．ホフマン−ラ ロシュ アーゲー 置換６，６−縮合窒素複素環化合物及びその使用
US20140371233A1 (en) * 2013-06-13 2014-12-18 Yale University COMPOSITIONS AND METHODS FOR TREATING Aß-MODULATED DISEASE OR DISORDER OR IMPROVING COGNITION IN A SUBJECT
JP2015521185A (ja) * 2012-05-15 2015-07-27 ノバルティス アーゲー Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するためのベンズアミド誘導体
US20160082015A1 (en) * 2013-04-18 2016-03-24 President And Fellows Of Harvard College Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3019175B1 (fr) * 2013-07-11 2019-12-04 The Trustees of Columbia University in the City of New York Microarn assurant le silençage de l'expression de la protéine tau
JPWO2018216705A1 (ja) * 2017-05-23 2020-03-26 国立大学法人京都大学 神経変性疾患の予防及び／又は治療剤

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008504022A (ja) * 2004-06-21 2008-02-14 プロティオーム・サイエンシィズ・ピーエルシー スクリーニング方法
JP2008511304A (ja) * 2004-09-02 2008-04-17 ニューロ セラピューティクス エービー ドーパミンニューロンの増強産生に関する方法と材料
JP2010505816A (ja) * 2006-10-03 2010-02-25 ヌリム・ファーマスーティカルズ・（１９９１）・リミテッド 治療薬剤としての置換アリール−インドール化合物とそのキヌレニン／キヌラミン様代謝産物
JP2014502601A (ja) * 2010-12-17 2014-02-03 エフ．ホフマン−ラ ロシュ アーゲー 置換６，６−縮合窒素複素環化合物及びその使用
WO2013166295A1 (fr) * 2012-05-02 2013-11-07 Georgetown University Traitement d'une maladie neurale avec des inhibiteurs de tyrosine kinase
JP2015521185A (ja) * 2012-05-15 2015-07-27 ノバルティス アーゲー Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するためのベンズアミド誘導体
US20160082015A1 (en) * 2013-04-18 2016-03-24 President And Fellows Of Harvard College Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders
US20140371233A1 (en) * 2013-06-13 2014-12-18 Yale University COMPOSITIONS AND METHODS FOR TREATING Aß-MODULATED DISEASE OR DISORDER OR IMPROVING COGNITION IN A SUBJECT

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ESTRADA, LISBELL D. ET AL.: "Reduction of Blood Amy loid- f3 Oligomers in Alzheimer's Disease Transgenic Mice by c-Abl Kinase Inhibition", JOURNAL OF ALZHEIMER'S DISEASE, vol. 54, no. 3, 2016, pages 1193 - 1205 *
PAGAN, FERNANDO ET AL.: "Nilotinib Effects in Parkinson's Disease and Dementia with Lewy Bodies", JOURNAL OF PARKINSON'S DISEASE, vol. 6, no. 3, 2016, pages 503 - 517, XP055571165, DOI: doi:10.3233/JPD-160867 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022137234A (ja) * 2017-05-23 2022-09-21 国立大学法人京都大学 神経変性疾患の予防及び／又は治療剤
JP7398831B2 (ja) 2017-05-23 2023-12-15 国立大学法人京都大学 神経変性疾患の予防及び／又は治療剤
WO2020241772A1 (fr) * 2019-05-31 2020-12-03 国立大学法人京都大学 Dispositif de traitement d'informations, dispositif de criblage, procédé de traitement d'informations, procédé de criblage, et programme
WO2020241836A1 (fr) * 2019-05-31 2020-12-03 国立大学法人京都大学 Dispositif de traitement d'informations, dispositif de criblage, procédé de traitement d'informations, procédé de criblage, et programme
WO2022124247A1 (fr) 2020-12-09 2022-06-16 国立大学法人 東京医科歯科大学 Agent de prévention ou de traitement de la dégénérescence lobaire fronto-temporale

Also Published As

Publication number Publication date
JPWO2018216705A1 (ja) 2020-03-26
JP7398831B2 (ja) 2023-12-15
JP2022137234A (ja) 2022-09-21

Similar Documents

Publication Publication Date Title
JP7398831B2 (ja) 神経変性疾患の予防及び／又は治療剤
US8591895B2 (en) Combinations for the treatment of diseases involving cell proliferation
EP2785713B1 (fr) Nouveaux dérivés trifluorométhyl-oxadiazoles et leur utilisation dans le traitement de maladies
EP2813498B1 (fr) Composés pour la maladie d'Alzheimer
CN113181362B (zh) 用于预防和/或治疗肌萎缩性侧索硬化症的药剂
WO2009017453A1 (fr) Nouvelle combinaison thérapeutique d'antipsychotique et d'inhibiteur de gsk3 958
US20070078142A1 (en) Treatment of tuberous sclerosis associated neoplasms
WO2009017455A1 (fr) Nouvelle combinaison (a) d'agoniste alpha-4-bêta-2-neuronal nicotinique et (b) d'inhibiteur de gsk3
JP2007509106A5 (fr)
JP2020059711A (ja) 自閉症を治療するための医薬組成物
US20200323828A1 (en) Methods of treating behavior alterations
RU2304436C2 (ru) Применение производных n-фенил-2-пиримидинамина против основывающихся на мастоцитах заболеваний, подобных аллергическим нарушениям
IL268125B2 (en) Pridopidine for the treatment of fragile x syndrome
US20220288207A1 (en) Photo induced control of protein destruction
JP3274579B2 (ja) 脳血管障害に伴う精神症候治療剤
CA2413277A1 (fr) Utilisation d'inhibiteurs de proteine de transfert de triglycerides microsomale (mtp) pour abaisser les particules de lipoproteine a forte teneur en triglycerides postprandiaux
US20080234285A1 (en) Combination of Organic Compounds
KR102220260B1 (ko) 스트레스-유도성 p-tau 를 낮추는 트리아졸로피리딘 및 트리아졸로피리미딘
JP2023154067A (ja) 筋萎縮性側索硬化症の予防及び／又は治療剤
US20220008409A1 (en) Cancer combination therapy using quinoline carboxamide derivative
JP2010531854A5 (fr)
KR20180037975A (ko) 포도막 흑색종을 치료하기 위한 mdm2 억제제
EA202192180A1 (ru) Ингибитор киназы atr bay 1895344 для применения для лечения гиперпролиферативного заболевания
US20130131079A1 (en) Flufenoxine derivatives for the treatment and prevention of amyloid pathologies
RU2799049C2 (ru) Способы лечения изменений поведения

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18806374

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019520270

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18806374

Country of ref document: EP

Kind code of ref document: A1